Golareh Habibi

Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes (2008)

Habibi, Golareh, Leung, Samuel, Law, Jennifer H, Gelmon, Karen, Masoudi, Hamid, Turbin, Dmitry, ...

Abstract Introduction Gene expression analysis is used to subtype breast cancers such that the most aggressive tumors are identified, but translating this into clinical practice can be cumbersome....

Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy (2007)

Stratford, Anna L, Habibi, Golareh, Astanehe, Arezoo, Jiang, Helen, Hu, Kaiji, Park, Eugene, ...

Abstract Introduction Basal-like breast cancers (BLBCs) are very aggressive, and present serious clinical challenges as there are currently no targeted therapies available. We determined the...

Urokinase-type Plasminogen Activator (uPA) is Inhibited with QLT0267 a Small Molecule Targeting Integrin-linked Kinase (ILK) (2007)

Nancy Dos Santos, Golareh Habibi, Michelle Wang, Jennifer H. Law, Heather N. Andrews, Daniel Wei, ...

Urokinase-type plasminogen activator (uPA) is associated with cancer recurrence where the most evidence comes from studies in breast cancer. According to the European Organization for Research and...

Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy

Stratford, Anna L, Habibi, Golareh, Astanehe, Arezoo, Jiang, Helen, Hu, Kaiji, Park, Eugene, ...